PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32326356-6	2020	In this study, we found that sequential, but not concurrent, treatment of cancer cells with interferon beta (IFNbeta), a type I IFN, and cisplatin (an inefficient ICD inducer) can enhance the expression of ICD biomarkers in cancer cells, including surface translocation of an endoplasmic reticulum (ER) chaperone, calreticulin (CRT), and phosphorylation of the eukaryotic translation initiation factor alpha (eIF2alpha).	Cisplatin	137-146	calreticulin	Homo sapiens	314-326	
32326356-6	2020	In this study, we found that sequential, but not concurrent, treatment of cancer cells with interferon beta (IFNbeta), a type I IFN, and cisplatin (an inefficient ICD inducer) can enhance the expression of ICD biomarkers in cancer cells, including surface translocation of an endoplasmic reticulum (ER) chaperone, calreticulin (CRT), and phosphorylation of the eukaryotic translation initiation factor alpha (eIF2alpha).	Cisplatin	137-146	calreticulin	Homo sapiens	328-331	
32326356-8	2020	Further bioinformatics and in vitro experimental analyses found that interferon regulatory factor 1 (IRF1) acted as an essential mediator of surface CRT exposure by sequential IFNbeta-cisplatin combination.	Cisplatin	184-193	calreticulin	Homo sapiens	149-152	
21151176-2	2011	This failure to induce immunogenic cell death can be attributed to CDDP"s incapacity to elicit the translocation of calreticulin (CRT) from the lumen of the endoplasmic reticulum (ER) to the cell surface.	Cisplatin	67-71	calreticulin	Homo sapiens	116-128	
21151176-2	2011	This failure to induce immunogenic cell death can be attributed to CDDP"s incapacity to elicit the translocation of calreticulin (CRT) from the lumen of the endoplasmic reticulum (ER) to the cell surface.	Cisplatin	67-71	calreticulin	Homo sapiens	130-133	
21151176-5	2011	Using a screening method that monitors the voyage of CRT from the ER lumen to the cell surface, we identified thapsigargin (THAPS), an inhibitor of the sarco/ER Ca(2+)-ATPase as a molecule that on its own does not stimulate CRT exposure, yet endows CDDP with the capacity to do so.	Cisplatin	249-253	calreticulin	Homo sapiens	53-56	
21151176-6	2011	The combination of ER stress inducers (such as THAPS or tunicamycin) and CDDP effectively induced the translocation of CRT to the plasma membrane, as well as immunogenic cell death, although ER stress or CDDP alone was insufficient to induce CRT exposure and immunogenic cell death.	Cisplatin	73-77	calreticulin	Homo sapiens	119-122	
21151176-6	2011	The combination of ER stress inducers (such as THAPS or tunicamycin) and CDDP effectively induced the translocation of CRT to the plasma membrane, as well as immunogenic cell death, although ER stress or CDDP alone was insufficient to induce CRT exposure and immunogenic cell death.	Cisplatin	73-77	calreticulin	Homo sapiens	242-245	
21151176-6	2011	The combination of ER stress inducers (such as THAPS or tunicamycin) and CDDP effectively induced the translocation of CRT to the plasma membrane, as well as immunogenic cell death, although ER stress or CDDP alone was insufficient to induce CRT exposure and immunogenic cell death.	Cisplatin	204-208	calreticulin	Homo sapiens	119-122	
29748013-8	2018	Overexpression of LIP restored cisplatin"s pro-apoptotic effect by activating CHOP/TRB3/caspase 3 axis and up-regulating calreticulin, that triggered MPM cell phagocytosis by dendritic cells and expanded autologous anti-tumor CD8+CD107+T-cytotoxic lymphocytes.	Cisplatin	31-40	calreticulin	Homo sapiens	121-133	
27446273-7	2016	In addition, the effects of capsaicin and cisplatin were evaluated for their abilities in inducing calreticulin membrane translocation and mediating ICD in human osteosarcoma cells (MG-63).	Cisplatin	42-51	calreticulin	Homo sapiens	99-111